Education
About Us
Working with TipRanks
Follow Us
Definitive Healthcare Corp (DH)
NASDAQ:DH
Top Page
Definitive Healthcare Corp
(NASDAQ:DH)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(32.74% Upside)
Action:ReiteratedDate:03/02/26
The score is held down primarily by weak financial performance (revenue contraction and ongoing losses) and very bearish technicals (strong downtrend with negative momentum). The earnings call provides partial offset via strong adjusted profitability/cash generation and operational progress, but guidance still points to further top-line decline, while valuation support is limited by negative earnings and no dividend.
Positive Factors
Recurring subscription (SaaS) revenue model
A largely subscription-based SaaS model provides durable, predictable recurring revenue and multiple expansion levers (add‑ons, users, data modules). That structural revenue mix supports retention-led growth, smoother cash conversion, and clearer unit economics over the next 2–6 months.
Materially reduced leverage / stronger balance sheet
Debt reduction to very low levels meaningfully lowers financial risk and interest burden, increasing strategic flexibility. With a stronger balance sheet the company can sustain short-term investment in retention, product integrations, or M&A while navigating current revenue pressure.
Positive cash generation and strong adjusted profitability
Sizable TTM free cash flow and an above-guidance adjusted EBITDA margin (32% in the quarter) indicate the business converts revenue to cash efficiently. Durable cash generation supports operations, funds product/market initiatives and reduces reliance on external financing despite GAAP losses.
Negative Factors
Sharp recent revenue decline
A large year‑over‑year revenue drop materially reduces scale and weakens operating leverage inherent to SaaS. Sustained top-line contraction compresses reinvestment capacity, makes retention/upsell harder to offset churn, and challenges the company’s path back to consistent growth.
Persistent GAAP losses and negative net margins
Continued net losses mean the equity base is not generating positive returns, constraining return on invested capital and shareholder value creation. Even with positive cash flow, structural unprofitability limits reinvestment and makes the company more sensitive to revenue shocks.
Concentration exposure to life sciences budgets
Heavy exposure to biopharma buying cycles and budget discipline is a structural headwind: when life sciences demand weakens, upsell and renewal opportunities decline. This concentration risk can prolong top-line recovery and makes revenue more sensitive to sector funding cycles.
Definitive Healthcare Corp (DH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$161.38M
Dividend YieldN/A
Average Volume (3M)338.90K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue Growth-5.30%
EPS Growth46.01%
CountryUS
Employees782
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.06
Shares Outstanding104,472,374
10 Day Avg. Volume311,870
30 Day Avg. Volume338,897
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.09
Price to Sales (P/S)1.27
P/FCF Ratio8.26
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue0.53
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$3.06Price Target Upside170.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.18
Revenue Forecast (FY)$223.61M
Definitive Healthcare Corp Business Overview & Revenue Model
Company DescriptionDefinitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution. The company's platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
How the Company Makes MoneyDefinitive Healthcare Corp generates revenue primarily through subscription-based services that give clients access to its extensive healthcare data and analytics platform. The company offers various subscription tiers, allowing clients to choose packages that best fit their needs. Key revenue streams include licensing fees for its data products, consulting services, and tailored analytics solutions. Additionally, DH has established partnerships with key industry players, enhancing its data offerings and broadening its market reach. The company's focus on continuous innovation and expanding its data capabilities also contributes to its earnings by attracting new customers and retaining existing ones.
Definitive Healthcare Corp Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but stabilizing picture: strong profitability, cash generation and operational progress (claims data remediation, faster integrations, digital activation traction and AI roadmap) are meaningful positives, while top-line weakness, reduced multi-year contract durations, and soft net dollar retention/upsell pressure continue to weigh on near-term growth. Management guided conservatively for 2026 with continued investment in product and integrations and expects NDR and revenue to improve later in the year as those investments and data fixes take hold.Q4-2025 Updates
Positive Updates
Q4 Profitability Above Guidance
Adjusted EBITDA of approximately $18.1M in Q4 2025 representing a 29% margin, about $1.1M above the high end of guidance and expanding ~120 basis points year-over-year.
Strong Free Cash Flow Generation
Trailing 12‑month unlevered free cash flow of ~$54.9M (~$55M) with adjusted EBITDA to unlevered FCF conversion of 78% (87% when adjusting for one-time CapEx), providing flexibility to invest while maintaining margins.
Productivity of Professional Services & Digital Activations
Professional services revenue grew ~49% year-over-year in Q4 2025, driven in part by a ramp in digital activations and analytics engagements; nearly 30 agency partners signed for digital activation with >1/3 already generating bookings.
Claims Data Remediation and Data Differentiation
Released a fall expansion pack and brought a new claims data source online in H2 2025, restoring claims volumes to above historical levels; added mobile phone data to strengthen reference and affiliation datasets, supporting long-term data differentiation.
Operational Integration and Faster Time-to-Value
Deepened integrations (Snowflake, Databricks, HubSpot; Salesforce pilot) and shortened time to integrate by ~25% in 2025; added >60 integrated customers in Q4 (160 for the full year), improving retention prospects.
Improving Retention Trajectory
Gross dollar retention improved ~2 percentage points year-over-year and retention rates improved year-over-year for each of the last three quarters; cohort analysis showed ~200 bps improvement for post-Q1 '24 sold business.
Disciplined Cost Management with Targeted Investment
Despite top-line pressure, the company maintained strong margins and disciplined costs while increasing capitalized software spend to ~$6M (a $5M increase YoY) to restart organic innovation and invest in AI-enabled product road map.
Clear AI & GTM Tailwinds Identified
Plan to embed Gen AI into flagship View platform starting next quarter; company cites proprietary, longitudinal data (15+ years) and domain expertise as competitive advantages, with ~2,300 customers and ~50% already integrating data into systems of record/insight.
Negative Updates
Top-Line Pressure and Revenue Declines
Q4 2025 revenue of $61.5M declined 1% year-over-year; full year 2025 revenue was $241.5M, down 4% YoY. Guidance for 2026 projects revenue of $220M–$226M, a further 6%–9% decline year-over-year.
Net Dollar Retention Weakness
Net dollar retention declined in 2025 due to ongoing pressure on upsell motions; management expects only a modest improvement of a couple points in NDR in 2026 and views 2025 as the bottom.
Contract Duration & RPO Headwinds
Total remaining performance obligations declined ~18% year-over-year; current RPO of $165M was flat sequentially but down ~12% YoY. cRPO dynamics were negatively impacted by a shift to more 1‑year deals, reducing multi-year commitments (cRPO related to multi-year commitments dropped from ~$100M at end of 2024 to ~$85M).
Negative Operating Leverage Risk in 2026
Company expects most of the 2026 revenue decrease to flow through due to largely fixed cost base, producing negative operating leverage. Full-year adjusted EBITDA margin is guided to 24%–26% in 2026 vs. 29% in 2025 (a margin decline driven by lower revenue and non-repeat of one-time credits).
Conversion & Cash Flow Pressures vs Prior Year
Operating cash flow for 2025 was $53.8M, down ~8% YoY. Adjusted EBITDA-to-unlevered-FCF conversion declined ~14 points YoY to 78% (though management cites adjustments to normalize conversion).
Near-Term Revenue Guidance Indicates Further Decline
Q1 2026 revenue guidance of $54M–$56M implies a 5%–9% YoY decline; management notes Q1 contains a large portion of annual renewals and only modest improvement in renewal rates was realized in Q4, stressing near-term top-line risk.
Upsell/Cross-sell Recovery Timing Uncertain
Despite remediation of claims data and product improvements, management acknowledges that benefits will take time to fully realize; upsell and cross-sell motions (key to NDR recovery) are expected to improve later in 2026 rather than immediately.
Company Guidance
The company guided Q1 2026 revenue of $54.0M–$56.0M (down 5%–9% YoY), adjusted operating income of $9.5M–$10.5M, adjusted EBITDA of $12M–$13M (22%–23% margin) and adjusted net income of $4M–$5M (~$0.03 per diluted share on ~143.2M W.A. shares). For full-year 2026 they forecast revenue of $220M–$226M (down 6%–9% YoY), adjusted operating income of $41.5M–$46.5M, adjusted EBITDA of $53M–$58M (24%–26% margin), adjusted net income of $21M–$26M and EPS of $0.14–$0.17 on ~145.4M shares; revenue dollars are expected to be roughly flat sequentially with a modest H2 uptick. Expense mix guidance calls for sales & marketing of 32%–33% of revenue, development 12%–13% and G&A 12%–13%, with targeted growth investments offset by cost efficiencies; management also expects adjusted EBITDA-to-unlevered-free-cash-flow conversion to improve by several points in 2026 given lower planned CapEx.Definitive Healthcare Corp Financial Statement Overview
Summary
Revenue has recently declined sharply and the company remains deeply unprofitable, which meaningfully weakens financial quality. Offsetting factors include strong gross margins, consistently positive operating/free cash flow, and a materially de-risked balance sheet in 2025 from significant debt reduction.Income Statement
Revenue has stalled and recently declined (down ~31% in 2025 vs. 2024 after roughly flat growth in 2024). Gross margins remain strong (~76–81%), but the business is deeply unprofitable: net margins were materially negative each year and widened sharply in 2023–2024 before improving in 2025 (still a large loss). The trajectory suggests cost structure and/or non-operating items have overwhelmed solid gross profitability, making earnings quality and visibility weak.22
Negative
Balance Sheet
Leverage improved dramatically in 2025, with total debt dropping to a very low level and debt-to-equity falling from ~0.57 (2024) to ~0.02 (2025), which meaningfully reduces financial risk. Equity remains sizable, supporting balance sheet stability. The key weakness is persistently negative returns on equity due to ongoing losses, indicating the capital base is not currently generating shareholder returns.64
Positive
Cash Flow
Cash generation is a relative bright spot: operating cash flow and free cash flow are positive across all years provided. However, free cash flow declined in 2025 (down ~19% vs. 2024), and cash flow has not been strong enough to offset the scale of net losses (coverage of net income remains well below 1). Overall, liquidity support from cash flow is helpful, but durability is a question if profitability does not improve.58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 241.52M | 252.20M | 251.41M | 222.65M | 166.15M |
| Gross Profit | 183.28M | 197.47M | 203.93M | 180.03M | 125.47M |
| EBITDA | -162.15M | -567.24M | -241.23M | 26.23M | 23.08M |
| Net Income | -138.93M | -413.12M | -202.39M | -7.22M | -51.91M |
Balance Sheet | |||||
| Total Assets | 735.49M | 1.09B | 1.83B | 2.12B | 2.12B |
| Cash, Cash Equivalents and Short-Term Investments | 180.89M | 290.16M | 308.07M | 331.87M | 387.50M |
| Total Debt | 177.82M | 253.11M | 267.93M | 275.85M | 270.68M |
| Total Liabilities | 356.50M | 482.19M | 626.73M | 640.68M | 617.78M |
| Stockholders Equity | 281.11M | 444.38M | 861.36M | 948.92M | 871.31M |
Cash Flow | |||||
| Free Cash Flow | 37.06M | 45.85M | 38.21M | 27.25M | 18.48M |
| Operating Cash Flow | 53.78M | 58.20M | 41.19M | 35.58M | 25.21M |
| Investing Cash Flow | 153.88M | -26.41M | -31.78M | -248.90M | -46.73M |
| Financing Cash Flow | -150.79M | -56.75M | -25.58M | -26.70M | 384.37M |
Definitive Healthcare Corp Technical Analysis
Negative
1.13
Price Trends
1.91
Negative
2.29
Negative
3.05
Negative
Market Momentum
-0.22
Negative
23.79
Positive
35.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DH, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.91, and below the 200-day MA of 3.05, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 23.79 is Positive, neither overbought nor oversold. The STOCH value of 35.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DH.
Definitive Healthcare Corp Risk Analysis
Definitive Healthcare Corp disclosed 74 risk factors in its most recent earnings report. Definitive Healthcare Corp reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Definitive Healthcare Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $595.93M | 37.76 | 5.87% | 0.52% | 3.68% | 5.62% | |
62 Neutral | $767.37M | 31.72 | 4.84% | ― | 1.30% | ― | |
60 Neutral | $661.35M | 78.87 | -1.85% | ― | 14.33% | 93.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $161.38M | -2.20 | -47.69% | ― | -5.30% | 46.01% | |
46 Neutral | $333.80M | -0.27 | -69.22% | ― | -16.65% | -71.92% |
* Healthcare Sector Average
DH
Definitive Healthcare Corp
1.10
-1.57
-58.80%
HSTM
HealthStream
20.97
-9.91
-32.10%
EVH
Evolent Health
3.02
-6.97
-69.77%
PHR
Phreesia
10.99
-15.94
-59.19%
GDRX
GoodRx Holdings
2.22
-2.24
-50.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.